Aegerion Pharmaceuticals (NASDAQ:AEGR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, AnalystRatingsNetwork.com reports. According to Zacks, “Aegerion’s third quarter results were better-than-expected with the company beating on the top- and bottom-line. The company also raised its revenue outlook for 2015. Aegerion continues to […]
